Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Name: Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
Published: 2016
License: Public Domain

National Cancer Institute (NCI) · 2016

ClinicalTrials.gov · Datasets · License: Public Domain · 2016

Open Source ↗

adult solid neoplasm, estrogen receptor negative, fallopian tube serous neoplasm, her2/neu negative, ovarian serous adenocarcinoma, ovarian serous tumor, primary peritoneal serous adenocarcinoma, progesterone receptor negative, recurrent breast carcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 889350
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.